Home
APLS
APLS News

Latest Apellis Pharmaceuticals Inc. (APLS) News on April 19, 2025

MT Newswires

2 days ago

BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

Zacks

4 days ago

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

MT Newswires

16 days ago

RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

Zacks

17 days ago

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases

Pharmaceutical Technology

17 days ago

FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases

MT Newswires

18 days ago

Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

GlobeNewswire

18 days ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Exploring US High Growth Tech Stocks In March 2025

Simply Wall St.

19 days ago

Exploring US High Growth Tech Stocks In March 2025

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey

25 days ago

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

TipRanks

a month ago

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Benzinga

a month ago

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

MT Newswires

a month ago

UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

Zacks

2 months ago

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $29 From $30, Keeps Neutral Rating

MT Newswires

2 months ago

RBC Trims Price Target on Apellis Pharmaceuticals to $25 From $26, Keeps Sector Perform Rating

Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

2 months ago

Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

GuruFocus.com

2 months ago

Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

Zacks

2 months ago

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

MT Newswires

2 months ago

Sector Update: Health Care Stocks Steady Pre-Bell Friday

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

Zacks

2 months ago

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

2 months ago

Apellis Pharmaceuticals Q4 Net Loss Narrows, Revenue Rises

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

2 months ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

What To Expect From Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings

GuruFocus.com

2 months ago

What To Expect From Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

2 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

2 months ago

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey

2 months ago

Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

2 months ago

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

2 months ago

High Growth Tech Stocks In The United States To Watch

Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?

Insider Monkey

2 months ago

Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?

MT Newswires

2 months ago

Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

GlobeNewswire

2 months ago

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January

Insider Monkey

2 months ago

Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

2 months ago

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past week

Simply Wall St.

2 months ago

Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past week

Why Insiders Are Selling Apellis Pharmaceuticals, Inc. (APLS) Recently

Insider Monkey

2 months ago

Why Insiders Are Selling Apellis Pharmaceuticals, Inc. (APLS) Recently

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday

MT Newswires

3 months ago

Sector Update: Health Care

MT Newswires

3 months ago

Apellis Pharmaceuticals' Geographic Atrophy Treatment Gets Approval From Australian Therapeutic Goods Administration

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

GlobeNewswire

3 months ago

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

MT Newswires

3 months ago

Apellis Pharmaceuticals Insider Sold Shares Worth $412,296, According to a Recent SEC Filing

MT Newswires

3 months ago

Wedbush Raises Price Target on Apellis Pharmaceuticals to $30 From $25, Keeps Neutral Rating

MT Newswires

3 months ago

Apellis Shares Rise After Reporting Preliminary Q4, Full-Year Product Sales Results

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Apellis Announces Keli Walbert to Join the Board of Directors

GlobeNewswire

3 months ago

Apellis Announces Keli Walbert to Join the Board of Directors

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

RBC Raises Price Target on Apellis Pharmaceuticals to $26 From $24, Keeps Sector Perform Rating

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Exploring 3 High Growth Tech Stocks In The United States

Simply Wall St.

4 months ago

Exploring 3 High Growth Tech Stocks In The United States

MT Newswires

4 months ago

Goldman Sachs Downgrades Apellis Pharmaceuticals to Neutral From Buy, $36 Price Target

Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?

Zacks

4 months ago

Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?

Should You Hold Apellis Pharmaceuticals (APLS)?

Insider Monkey

4 months ago

Should You Hold Apellis Pharmaceuticals (APLS)?

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

Zacks

4 months ago

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?

Zacks

4 months ago

Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

5 months ago

Exploring Three High Growth Tech Stocks in the United States

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire

5 months ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

GlobeNewswire

5 months ago

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

Apellis price target lowered to $30 from $43 at Wells Fargo

TipRanks

5 months ago

Apellis price target lowered to $30 from $43 at Wells Fargo

Apellis price target lowered to $47 from $61 at BofA

TipRanks

5 months ago

Apellis price target lowered to $47 from $61 at BofA

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Zacks

5 months ago

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

MT Newswires

5 months ago

RBC Capital Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Maintains Sector Perform Rating

MT Newswires

5 months ago

Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $40 From $65, Maintains Outperform Rating

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ...

GuruFocus.com

5 months ago

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ...

Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday

Motley Fool

5 months ago

Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday

MT Newswires

5 months ago

Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $25 From $27, Maintains Neutral Rating

Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

5 months ago

Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say

Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales

Investor's Business Daily

5 months ago

Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales

High Growth Tech Stocks to Watch in November 2024

Simply Wall St.

5 months ago

High Growth Tech Stocks to Watch in November 2024

MT Newswires

5 months ago

Apellis Pharmaceuticals Q3 Loss Narrows, Revenue Gains -- Shares Fall Pre-Bell

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates

Zacks

5 months ago

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

GlobeNewswire

5 months ago

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look For

GuruFocus.com

5 months ago

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look For

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

6 months ago

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know

Zacks

6 months ago

Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know

1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

Motley Fool

6 months ago

1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

Apellis, Sobi announced results from Phase 3 VALIANT study

TipRanks

6 months ago

Apellis, Sobi announced results from Phase 3 VALIANT study

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

GlobeNewswire

6 months ago

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

MT Newswires

6 months ago

Mizuho Trims Price Target on Apellis Pharmaceuticals to $38 From $39, Keeps Neutral Rating

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

GlobeNewswire

6 months ago

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

Benzinga

6 months ago

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

MT Newswires

6 months ago

William Blair Initiates Apellis Pharmaceuticals at Outperform

MT Newswires

6 months ago

Scotiabank Initiates Apellis Pharmaceuticals at Sector Perform With $35 Price Target

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

GlobeNewswire

6 months ago

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Should You Hold Apellis Pharmaceuticals (APLS)?

Insider Monkey

7 months ago

Should You Hold Apellis Pharmaceuticals (APLS)?

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

GlobeNewswire

7 months ago

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU

Zacks

7 months ago

Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU

Apellis Stock Hammered After Eye Drug Gets A Third European Rejection

Investor's Business Daily

7 months ago

Apellis Stock Hammered After Eye Drug Gets A Third European Rejection

MT Newswires

7 months ago

Sector Update: Health Care

MT Newswires

7 months ago

Apellis European Rejection for Vision Treatment Dents Revenue Growth, Stock Performance, Wedbush Says

MT Newswires

7 months ago

--Wedbush Cuts Price Target on Apellis Pharmaceuticals to $35 From $41, Maintains Neutral Rating; Shares Fall

MT Newswires

7 months ago

Sector Update: Health Care Stocks Rise Premarket Friday

MT Newswires

7 months ago

Sector Update: Health Care

Apellis eye drug again turned back in Europe

BioPharma Dive

7 months ago

Apellis eye drug again turned back in Europe

MT Newswires

7 months ago

Apellis Pharmaceuticals Gets Reaffirmed Negative CHMP Opinion on Pegcetacoplan for Geographic Atrophy

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

GlobeNewswire

7 months ago

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

MT Newswires

7 months ago

Apellis Pharmaceuticals Insider Sold Shares Worth $1,340,597, According to a Recent SEC Filing

Apellis Pharmaceuticals, Inc. (APLS): Among Hedge Funds’ Top Biotech Stock Picks

Insider Monkey

7 months ago

Apellis Pharmaceuticals, Inc. (APLS): Among Hedge Funds’ Top Biotech Stock Picks

Share on Social Networks: